Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
REPL Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Replimune Group, Inc.NASDAQ: REPL
Operating Expenses · Q3 FY2026 · quarter ended Dec 2025
Operating expenses grows, but more slowly than its trailing trend
Q3 FY2026 operating expenses of $71.87M rose 8.9% year over year, behind the +35.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 14.7% from the prior quarter. Over 3 fiscal years it compounded at +30.8% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +8.9% toward the trailing-twelve-month pace of +35.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 261.63M USD
- Year-over-year change
- +11.4%
- 4-year CAGR
- +35.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 261.63M | +11.4% |
| FY2024 | 2024-03-31 | 234.77M | +32.6% |
| FY2023 | 2023-03-31 | 177.08M | +51.5% |
| FY2022 | 2022-03-31 | 116.91M | +48.7% |
| FY2021 | 2021-03-31 | 78.62M | — |
Operating Expenses vs competitors
How REPL compares with its peers on the latest reported figures
- REPL's LTM Dec 2025 operating expenses of $325.61M is the 3rd highest of the 11 companies compared; the peer median is $171.1M.
- Its year-over-year change of +35.1% is the 3rd highest of 10, against a peer median of -10.4%.
- Over three fiscal years its annual growth of +30.8% compares with a peer median of -9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $450.66M | +32.9% | +1.6% | 246.8% | |
| LTM Sep 2026 | $432.13M | -11.1% | +7.0% | 114.0% | |
| LTM Dec 2025 | $325.61M | +35.1% | +30.8% | — | |
| LTM Aug 2026 | $317.52M | +142.5% | +109.8% | 45.2% | |
| LTM Mar 2026 | $189.56M | -47.4% | -10.9% | 611487.1% | |
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $168.69M | +127.4% | +30.3% | 780.5% | |
| LTM Mar 2026 | $99.95M | -10.4% | -13.9% | 281.2% | |
| LTM Mar 2026 | $56.39M | -15.6% | -12.1% | 45.5% | |
| LTM Jun 2024 | $36.55M | — | -32.2% | 4480.0% | |
| LTM Mar 2026 | $33.28M | -2.6% | -8.4% | 45.8% | |
| Peer median (excluding REPL) | $171.1M | -10.4% | -9.7% | 180.4% | |
Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.14M | 4.58M | 0 | 0 | 0 |
| Gross Profit | (4.14M) | (4.58M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 57.49M | 80.65M | 126.53M | 174.96M | 189.45M |
| Selling, General & Admin | 21.13M | 36.26M | 0 | 0 | 0 |
| Operating Expenses | 78.62M | 116.91M | 177.08M | 234.77M | 261.63M |
| Depreciation & Amortization | 4.14M | 4.58M | 2.45M | 5.08M | 5.93M |
| EBITDA | (76.48M) | (114.41M) | (171.72M) | (227.77M) | (253.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (82.76M) | (121.48M) | (177.08M) | (234.77M) | (261.63M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 916K | 390K | 10.01M | 23.36M | 21.12M |
| Interest Expense | 3.06M | 2.22M | 4.16M | 6.66M | 7.89M |
| Other Income / Expenses | (915K) | 278K | 3.08M | 19.39M | 14.8M |
| Income Before Tax | (83.68M) | (121.21M) | (174M) | (215.39M) | (246.83M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.81M) | (3.17M) | 288K | 408K | 468K |
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| EPS (Diluted) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| Weighted Avg Shares | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
| Weighted Avg Shares (Diluted) | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
Replimune Group, Inc.
NASDAQ:REPL
Intrinsic Alpha fair value
Locked
Current Price
$19.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.